Skip to content

The effect of Surgiflo use on perioperative blood loss in total knee arthroplasty

The effect of Surgiflo use on perioperative blood loss in total knee arthroplasty

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065419
Enrollment
Unknown
Registered
2022-11-04
Start date
2022-11-04
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative blood loss

Interventions

treatment group:Surgiflo
control group:routine hemostasis

Sponsors

ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50-80 years; 2. Meet the 2018 Chinese guideline for diagnosis and treatment of osteoarthritis; 3. Preoperative venous ultrasonography exclude deep venous thrombosis; 4. Preoperative American Society of Anesthesiologists (ASA) Grade I or II; 5. Patients have good compliance and complete data; 6. The patient has a clear awareness, agrees to participate in this clinical trial, and signs the informed consent form in advance.

Exclusion criteria

Exclusion criteria: 1. Preoperative coagulation disorders; 2. Under anticoagulant therapy; 3. Preoperative deep venous thrombosis; 4. Severe hepatic insufficiency renal insufficiency cardiovascular disease or cancer.

Design outcomes

Primary

MeasureTime frame
total blood loss;

Secondary

MeasureTime frame
intraoperative blood loss,;hidden blood loss;percentage of hidden blood loss;blood transfusion rate;operation time;decrease in HB;wound dressing replacement frequency;postoperative knee swelling;Deep vein thrombosis (DVT) Occurrence;Visual Analogue Scale (VAS) score;Hospital for Special Surgery (HSS) score;range of motion;

Countries

China

Contacts

Public ContactHao Wang

ShangHai GuangHua Hospital of Integrated Traditional Chinese and Western Medicine

whjasonwang@foxmail.com+86 13918146170

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026